| Line Item | 2025-10-31 | Y/Y |
|---|---|---|
| Revenue | $6.95B | +6.7% |
| Cost of Revenue | $3.31B | +11.1% |
| R&D Expense | $455.0M | -5.0% |
| SG&A Expense | $1.71B | +9.0% |
| Operating Income | $1.48B | -0.6% |
| Interest Expense | $112.0M | +16.7% |
| Pre-tax Income | $1.44B | -5.7% |
| Income Tax | $132.0M | -43.1% |
| Net Income | $1.30B |
| Line Item | 2025-10-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.79B | +34.6% |
| Accounts Receivable | $1.49B | +12.3% |
| Inventory | $1.02B | +5.5% |
| Current Assets | $4.59B | +16.0% |
| Total Assets | $12.73B | +7.4% |
| Current Liabilities | $2.35B | +23.9% |
| Long-term Debt | $3.05B | -8.8% |
| Line Item | 2025-10-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $1.56B | -11.0% |
| Capital Expenditures | $407.0M | +7.7% |
| Investing Cash Flow | -$394.0M | +68.7% |
| Financing Cash Flow | -$715.0M | +4.9% |
| Free Cash Flow | $1.15B | -16.1% |
| +1.1% |
| EPS (Basic) | $4.59 | +3.4% |
| EPS (Diluted) | $4.57 | +3.2% |
| Total Liabilities |
| $5.99B |
| +0.6% |
| Stockholders' Equity | $6.74B | +14.3% |